Ortho-K or Atropine: Choosing a Myopia Treatment

Once a family has decided to do something about a child's progressing myopia, the next question is which method. There are three with genuine evidence behind them, and the honest answer is that the differences between them matter less than whether the child will actually use the one you choose.

The three options

Overnight Ortho-K

A custom rigid lens worn during sleep reshapes the corneal surface. The child wakes, removes the lenses, and sees clearly all day with nothing on their eyes. The reshaped cornea also produces the peripheral defocus profile that slows elongation.

Soft multifocal contact lenses

Specific daytime soft lens designs carry concentric power zones producing the same peripheral effect. Worn during waking hours like any contact lens.

Low dose atropine

One drop at bedtime at a concentration far below that used for dilation. It does not correct vision, so glasses continue to be worn.

Side by side

How to actually decide

In practice the decision usually comes down to three questions.

Does the child want to be free of glasses?

If yes, and particularly if sport or swimming is involved, Ortho-K is usually the strongest candidate. It is the only option that leaves the child with nothing on their face for the entire waking day.

For a child who is perfectly happy in glasses and simply needs progression slowed, atropine is the lowest friction option by a wide margin.

Who is going to handle the lenses?

This is the question that determines whether a treatment survives contact with real family life.

Ortho-K handling happens at home, at bedtime, with a parent present. That makes it manageable for younger children in a way that daytime lenses are not, because a seven year old inserting a lens in a school bathroom is a different proposition entirely.

Soft multifocals suit children who are motivated, a bit older, and comfortable managing lenses independently.

Atropine requires one drop a night, which is the lowest handling burden of anything available.

How fast is the child progressing?

A child progressing rapidly despite a single treatment is a candidate for combination therapy. Low dose atropine alongside Ortho-K or soft multifocal lenses is a recognised approach, and the two mechanisms appear to be complementary rather than redundant.

What about the free option

Time outdoors is consistently associated with slower myopia onset and progression, at around two hours a day of daylight exposure. It costs nothing, carries no risk, and works alongside any of the three treatments.

It is not usually sufficient on its own for a child already progressing quickly, but it is the easiest thing on this page to start doing today.

How progress is measured

Prescription change is the number families notice, and axial length is the number that matters. A prescription can shift for reasons unrelated to eye growth, whereas axial length measures the physical change directly.

Baseline measurements are taken at the first appointment and compared at each review, usually every six to twelve months. That comparison is what turns myopia control from a hope into a measurement.

What a first appointment involves

• Full pediatric eye health assessment
• Refraction, cycloplegic where appropriate for accuracy in children
• Corneal topography
• Baseline measurements for future comparison
• A discussion of all three options with the family rather than a recommendation handed down

Bring previous prescriptions if you have them, even from another practice. Two or three years of history makes the rate of progression immediately visible, and that rate is the single most useful piece of information in choosing a treatment.

What the trials actually measured

Myopia control research is unusually consistent for a field this young, and knowing what was measured helps in judging the claims made about it.

The endpoint that matters is axial length, measured in millimetres, not prescription in dioptres. Prescription can move for reasons unrelated to eye growth, and it is the physical length of the eye that carries the lifetime risk. Any study or practitioner quoting only dioptres is measuring the less useful of the two.

Across independent trials, all three approaches produced meaningfully less axial elongation over two years than single vision glasses. Head to head comparisons between the three are fewer and less conclusive, which is the honest reason nobody should tell you one is definitively best.

What the trials also show, consistently, is a rebound question. Some studies of atropine found faster progression after stopping abruptly, which is why tapering rather than stopping is now usual. Overnight lens studies show the corneal effect reversing, as expected, with less clear evidence about progression afterwards.

What a year of treatment actually looks like

Whichever method you choose, the shape of the year is similar.

1. Baseline appointment. Full assessment, corneal mapping, axial length recorded. Sixty to ninety minutes.
2. Fitting or initiation. Immediate for atropine, days for soft multifocals, one to two weeks for custom overnight lenses.
3. Settling reviews. Dense in the first month for lens based methods, minimal for drops.
4. Six month review. Axial length compared against baseline. This is the first point at which anyone can say anything useful about whether it is working.
5. Twelve month review. The comparison that actually matters, and the point at which continuing, changing or combining gets decided.

The commitment is therefore roughly four to six appointments in year one and two a year thereafter, for as long as the child is progressing.

Cost, compared honestly

No figures appear here, because what you pay depends on your plan and the office gives you an exact number before anything is ordered. The shape of the spending is worth understanding though.

• Atropine is by a distance the cheapest. A compounded drop plus the appointments, and the child still needs glasses, which they would need anyway.
• Soft multifocal lenses carry an ongoing supply cost, comparable to any daily disposable, plus fitting and reviews.
• Ortho-K is the most front loaded. The fitting programme and custom lenses represent most of the cost, and lenses then last a year or more, so the ongoing cost drops sharply after year one.

Over five years the totals converge more than the first year suggests. Which is cheaper depends heavily on whether the child would have been wearing daily disposables anyway.

How to tell whether it is working

This is the question families find hardest to get a straight answer to, so here is the straight answer.

Compare axial length against your own child's baseline, at six and twelve months. A slower rate of elongation than the year before treatment started is the signal. Anything else, including how the child says their vision feels, is not evidence either way.

If progression continues at the same rate after a year of consistent, correctly used treatment, that is a reason to change or combine methods rather than to conclude nothing works.

Combining methods, and when it is considered

Combination therapy is increasingly common and it is worth knowing when it enters the conversation rather than being surprised by it.

The usual trigger is a child who continues to progress at close to their previous rate after a year of consistent single method treatment. Before concluding the method has failed, three things get checked: whether adherence is genuinely as good as reported, whether the lens fit or drop concentration is still appropriate, and whether the measurements being compared are reliable.

If progression is real and adherence is good, adding low dose atropine to a lens based method is the most common next step. The two work through different mechanisms, which is the rationale for expecting an additive effect rather than a redundant one.

What combination does not mean is doubling anything. The atropine concentration is the same low dose used alone, and the lens regime is unchanged. It also does not mean the first method was wasted, since the comparison that established the need came from tracking it.

Reviews continue at the same six to twelve month interval, measuring the same thing against the same baseline.